While ICI/VEGF are better than ICI/ICI for the treatment of mccRCC in patients with favorable risk groups, there is currently no consensus on whether ICI/ICI or ICI/VEGF shows the greatest therapeutic benefit for intermediate- or poor-risk disease groups, which make up approximately 75% of patients with advanced RCC. This evidence concerns the gene VEGFA and renal cell adenocarcinoma.